Nuvation Bio (Nuvation Bio) Marketable Securities : $568.56 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Nuvation Bio Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Nuvation Bio's Marketable Securities for the quarter that ended in Dec. 2023 was $568.56 Mil.

Nuvation Bio's annual Marketable Securities declined from Dec. 2021 ($632.97 Mil) to Dec. 2022 ($559.92 Mil) but then increased from Dec. 2022 ($559.92 Mil) to Dec. 2023 ($568.56 Mil).

Nuvation Bio Marketable Securities Historical Data

The historical data trend for Nuvation Bio's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio Marketable Securities Chart

Nuvation Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Marketable Securities

186.00

632.97

559.92

568.56

Nuvation Bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Marketable Securities	Get a 7-Day Free Trial											559.92	616.54	580.84	594.94	568.56

Nuvation Bio Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Nuvation Bio (NYSE:NUVB.WS) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Nuvation Bio Marketable Securities Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvation Bio (Nuvation Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

NUVB:USA

Address

1500 Broadway, Suite 1401, New York, NY, USA, 10036

Website

https://www.nuvationbio.com

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).